论文部分内容阅读
目的通过对Survivin蛋白在结直肠腺癌组织、腺瘤组织和癌旁正常组织中表达的研究,探索Survivin在结直肠腺癌发生发展过程中的表达水平。方法应用免疫组化法(immunohistochemistry,IHC)、原位杂交法(in situhybridization,ICH)检测Survivin在30例癌旁正常组织,60例结直肠腺瘤(37例伴中低度异型增生、23例伴重度异型增生),60例结直肠腺癌组织标本中的表达情况;结合临床资料分析其表达与临床病理特征间的关系。结果Survivin在癌旁正常组织、腺瘤伴中低度异型增生,腺瘤伴重度异型增生和结直肠腺癌组织中的阳性表达率分别为10.00%、13.51%、52.17%和73.34%。Survivin mRNA在癌旁正常组织、腺瘤伴中低度异型增生、腺瘤伴重度异型增生和结直肠腺癌组织中的阳性表达率分别为6.67%、10.81%、43.48%和63.33%。Survivin的表达与结直肠癌的肿瘤淋巴结转移(tumor node metastasis,TNM)分期、浸润深度、淋巴转移和肝转移具有相关性,而与患者性别、年龄、肿瘤大小、部位、分化程度和组织学类型无关。结论 Survivin在结直肠组织中不同程度的表达与结直肠黏膜癌变的发生、发展有密切关联,有望成为结直肠癌临床诊断及监测的一个特异性生物标志物。
Objective To investigate the expression of Survivin in colorectal adenocarcinoma through the expression of Survivin in colorectal adenocarcinoma, adenoma and adjacent normal tissues. Methods Survivin was detected by immunohistochemistry (IHC) and in situ hybridization (ICH) in 30 cases of adjacent normal tissues and 60 cases of colorectal adenomas (37 cases with moderate and low-grade dysplasia, 23 cases With severe dysplasia), 60 cases of colorectal adenocarcinoma tissue specimens of the expression; combined with clinical data analysis of its expression and clinicopathological characteristics of the relationship between. Results The positive rates of Survivin in adjacent normal tissues, adenomas with low-grade dysplasia, adenoma with severe dysplasia and colorectal adenocarcinoma were 10.00%, 13.51%, 52.17% and 73.34%, respectively. The positive rate of Survivin mRNA was 6.67%, 10.81%, 43.48% and 63.33% in the adjacent normal tissue, adenoma with low-grade dysplasia, adenoma with severe dysplasia and colorectal adenocarcinoma respectively. Survivin expression was correlated with tumor node metastasis (TNM) stage, depth of invasion, lymphatic metastasis and liver metastasis in colorectal cancer, but not with gender, age, tumor size, location, degree of differentiation and histological type Nothing to do Conclusion The expression of Survivin in colorectal tissues with different degrees is closely related to the occurrence and development of colorectal mucosa carcinogenesis, which is expected to become a specific biomarker for clinical diagnosis and monitoring of colorectal cancer.